Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

I-Mab Biopharma Co. Ltd.

www.i-mabbiopharma.com

Latest From I-Mab Biopharma Co. Ltd.

Finance Watch: Expect A Busy First Half For 2020 IPOs

Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.

Financing Business Strategies

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore

The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.

Deals Business Strategies

Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • I-Mab Biopharma Co. Ltd.
  • Senior Management
  • Jingwu Zang, MD, PhD, CEO
    Jielun Zhu, CFO
    Weimin Tang, PhD, EVP, Global Bus. Dev.
    Joan Huaqiong Shen, MD, PhD, Pres., R&D
  • Contact Info
  • I-Mab Biopharma Co. Ltd.
    Phone: 21 6057 8000
    Ste. 802, West Tower, 88 Shangke Rd.
    Pudong District
    Shanghai, 201210
    China
UsernamePublicRestriction

Register